Coagulation factor X human

DB13148

biotech approved investigational

Deskripsi

Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency.

Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. It is a two-chain glycoprotein with the molecular weight of approximately 59 kDa A31472. While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways. Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers A31471. Administration of coagulation Factor X from healthy donor serves to restore and achieve effective hemostasis.

Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors who have passed viral screening tests L41045.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Following a single intravenous dose of 25 IU/kg, the mean plasma half-life (CV%) was 30.3 (22.8) hr.[L41045]
Volume Distribusi Following a single intravenous dose of 25 IU/kg, the mean volume of distribution at steady state (CV%) was 56.3 (24.0) mL/kg [L41045].
Klirens (Clearance) Following a single intravenous dose of 25 IU/kg, the mean total body clearance was 1.35 (21.7) mL/kg/hr.[L41045]

Absorpsi

Following a single intravenous dose of 25 IU/kg, the mean peak plasma concentration (CV%) was 0.504 (17.2) IU/mL L41045.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

90 Data
Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor X human.
Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human.
Menadione Menadione may increase the thrombogenic activities of Coagulation factor X human.
Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Coagulation factor X human.
Aprotinin Aprotinin may increase the thrombogenic activities of Coagulation factor X human.
Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Coagulation factor X human.
Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation factor X human.
Camostat Camostat may increase the thrombogenic activities of Coagulation factor X human.
Menadione bisulfite Menadione bisulfite may increase the thrombogenic activities of Coagulation factor X human.
Monteplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Monteplase.
Lepirudin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.
Bivalirudin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Bivalirudin.
Alteplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Alteplase.
Urokinase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Urokinase.
Reteplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reteplase.
Anistreplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Anistreplase.
Tenecteplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tenecteplase.
Abciximab The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Abciximab.
Drotrecogin alfa The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Drotrecogin alfa.
Streptokinase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Streptokinase.
Dicoumarol The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dicoumarol.
Argatroban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Argatroban.
Ardeparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ardeparin.
Phenindione The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Phenindione.
Fondaparinux The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Fondaparinux.
Warfarin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Warfarin.
Pentosan polysulfate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Phenprocoumon.
Dipyridamole The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dipyridamole.
Heparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Heparin.
Enoxaparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Enoxaparin.
Epoprostenol The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Epoprostenol.
Acenocoumarol The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Coumarin.
Ximelagatran The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ximelagatran.
Desmoteplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Desmoteplase.
Defibrotide The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Defibrotide.
Ancrod The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ancrod.
Beraprost The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Beraprost.
Prasugrel The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Prasugrel.
Rivaroxaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Rivaroxaban.
Sulodexide The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Sulodexide.
Idraparinux The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Idraparinux.
Cangrelor The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Cangrelor.
Astaxanthin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Astaxanthin.
Apixaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Apixaban.
Otamixaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Otamixaban.
Amediplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Amediplase.
Dabigatran etexilate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran etexilate.
Danaparoid The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Danaparoid.
Dalteparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dalteparin.
Tinzaparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tinzaparin.
(R)-warfarin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Nadroparin.
Triflusal The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Triflusal.
Ticagrelor The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ticagrelor.
Ditazole The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Ditazole.
Vorapaxar The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Vorapaxar.
Edoxaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Edoxaban.
Sodium citrate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Sodium citrate.
Dextran The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dextran.
Bemiparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Bemiparin.
Parnaparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Parnaparin.
Desirudin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Desirudin.
Antithrombin Alfa The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Antithrombin III human.
Letaxaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Letaxaban.
Darexaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Darexaban.
Betrixaban The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Betrixaban.
Nafamostat The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Nafamostat.
Gabexate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Gabexate.
Fluindione The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Fluindione.
Brinase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Brinase.
Clorindione The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Clorindione.
Diphenadione The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Diphenadione.
Tioclomarol The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tioclomarol.
Melagatran The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Melagatran.
Saruplase The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Saruplase.
(S)-Warfarin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tocopherylquinone.
Dabigatran The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran.
Semuloparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Semuloparin.
Troxerutin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Troxerutin.
Edetic acid The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Edetic acid.
Reviparin The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reviparin.
Dermatan sulfate The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dermatan sulfate.
SR-123781A The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with SR-123781A.
Limaprost The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Limaprost.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 19141158
    Brown DL, Kouides PA: Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008 Nov;14(6):1176-82. doi: 10.1111/j.1365-2516.2008.01856.x.
  • PMID: 11867437
    Venkateswarlu D, Perera L, Darden T, Pedersen LG: Structure and dynamics of zymogen human blood coagulation factor X. Biophys J. 2002 Mar;82(3):1190-206. doi: 10.1016/S0006-3495(02)75476-3.
  • PMID: 25535411
    Palta S, Saroa R, Palta A: Overview of the coagulation system. Indian J Anaesth. 2014 Sep;58(5):515-23. doi: 10.4103/0019-5049.144643.

Contoh Produk & Brand

Produk: 12 • International brands: 0
Produk
  • Balfaxar
    Powder, for solution • - • Intravenous • US • Approved
  • Beriplex P/n 1000
    Powder, for solution • - • Intravenous • Canada • Approved
  • Beriplex P/n 500
    Powder, for solution • - • Intravenous • Canada • Approved
  • Coagadex
    Injection, powder, lyophilized, for solution; Kit • 100 [iU]/1mL • Intravenous • US • Approved
  • Coagadex
    Injection, powder, lyophilized, for solution; Kit • 100 [iU]/1mL • Intravenous • US • Approved
  • Coagadex
    Injection, powder, for solution • 250 IU • Intravenous • EU • Approved
  • Coagadex
    Injection, powder, for solution • 500 IU • Intravenous • EU • Approved
  • Feiba Vh Immuno Anti Inhibitor
    Powder, for solution • - • Intravenous • Canada • Approved
Menampilkan 8 dari 12 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul